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Abstract  
Introduction: The present study aimed to establish the epidemiological and clinical characteristics of patients who were histopathologically 
diagnosed with malignant melanoma (MM). Methods: The present study retrospectively analyzed the data of 78 patients who were 
histopathologically diagnosed with MM in Dicle University Medical Faculty, Dermatology and Medical Oncology departments between 2005 and 
2014. Results: The study included 78 patients in total with 44 (56.4%) male and 34 (43.6%) female. Median age of the patients was 62.50 years 
(range: 27 - 84 years). Of the patients, 78.2% (n=61) had cutaneous melanoma, 8.9% had solid organ melanoma, and 2.5% had ocular and 
mucosal melanoma. The most common tumor localization among the patients was the lower extremities with 29.4% (n=23). The most common 
histopathological type was nodular malignant melanoma with 35.8% (n=28). Based on TNM, Clark and Breslow classifications, 26.9% (n=21) of 
the patients were stage 4, 26.9% (n=21) were Clark stage 4, and 37.1% (n=29) were Breslow stage 4. Median overall survival in all patients was 
14.9 months (95% CI 10.9 - 18.8 months). In the multivariate Cox analysis, only stage statistically significantly affecting survival [odds ratio (OR): 
0.54; (95% CI 0.16-1.82, p=0.02)]. Conclusion: Malignant melanoma data are also important for the optimal utilization of effective methods and 
healthcare resources to prevent the disease. In order to minimize MM mortality and morbidity, not only the society but also physicians from 
primary and secondary care hospitals should become familiar with melanoma. 
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Introduction 
 
Malignant melanoma (MM) is a malignant tumor resulting from 
melanocytes and nevus cells that are considered to be formed 
through melanocyte differentiation. MM is the fifth most common 
cancer in males and the sixth most common cancer in females 
accounts for 5% of all newly-diagnosed cancers [1]. The estimated 
lifetime risk for developing invasive melanoma is 1:1,500 in the US. 
The incidence increases with age, particularly in males. In the US, 
the melanoma incidence under the age of 40 years is higher in 
females, whereas it is higher in males above the age of 40 years 
[1]. The melanoma incidence has shown a significant increase for 
the last few decades around the world. It exhibits significant 
differences in race and demographics, and it is one of the most 
common malignancies in Europe, North America, Australia, and New 
Zealand, especially in light-skinned individuals. It is more rarely 
seen in Africans, Latin Americans, Asians and dark-skinned 
individuals [2, 3]. Australia Queensland is considered the place with 
the highest MM incidence (51/100,000) in the world. For melanoma 
incidence, the worldwide annual mean is 3-7% in Caucasians and 
one- or two-fold increase is estimated once in 10 to 20 years [4, 5]. 
Seventy-five percent of deaths from skin cancers are due to 
melanoma. Due to the poor prognosis and fast course, it is also an 
important public health issue. Despite this, there are few studies 
demonstrating the epidemiology of cutaneous malignant melanoma 
in Turkey. A study that was conducted in 2006 in Turkey by 
collecting data from eight residential areas (Izmir, Eskisehir, 
Erzurum, Bursa, Edirne, Antalya, Trabzon, and Samsun), reported 
the melanoma incidence as 1.4/100,000. Based on the data from 
the Ministry of Health, melanoma incidence was 2.1/100,000 in 
males and 1.6/100,000 in females in 2009 in Turkey. Additionally, 
when 2009 data were compared to 2004 data (1.5/100,000 in males 
and 1.2/100,000 in females), it was seen that MM incidence has 
increased over the last six years [6, 7]. The present study aimed to 
establish the epidemiological and clinical characteristics of patients 
who were histopathologically diagnosed with MM in the 
Dermatology and Medical Oncology departments of our university 





The present study retrospectively analyzed the data of 78 patients 
who were histopathologically diagnosed with MM at Dicle University 
Medical Faculty, Dermatology and Medical Oncology departments 
between 2005 and 2014. Patient files and pathology reports were 
analyzed to record age at diagnosis, gender, date of diagnosis, date 
of exitus, tumor localization, overall survival times, histopathology 
[based on the American Joint Committee on Cancer (AJCC) 
classification], Breslow´s tumor thickness, Clark´s level of invasion, 
spontaneous regression and presence of ulceration, mitotic indices, 
presence of satellite nodules, capsule invasion and TNM stage. 
Metastasis regions at diagnosis and follow-up were recorded. 
Histopathologically, MM was classified as superficial spreading MM, 
nodular MM, lentigo MM, acral lentiginous MM, and those patients 
with only a malignant melanoma result on the pathology report 
were classified as unknown. Overall survival time of the patients 
was calculated as the time from the diagnosis date to the last 
control date. Descriptive statistics were expressed in mean ± 
standard deviation or median (minimum - maximum) for continuous 
variables, and in case number and (%) for categorical variables. In 
a comparison of the variables between different groups, the 
student's t-test was used for continuous variables and Pearson's chi-
square test was used for categorical variables. The overall survival 
was compared by the Kaplan-Meier method and log-rank test. 
Furthermore, the Kaplan-Meier method was employed again to 
estimate life expectancy and a 95% confidence intervals relating to 
each risk factor. All p values were calculated in the two-way analysis 
and p values < 0.05 were considered statistically significant. All 
statistical data were calculated in computer environment by a 






The study included 78 patients in total with 44 (56.4%) males and 
34 (43.6%) females. The median age of the patients was 62.50 
years (range: 27 - 84 years). The male/female ratio was 1:1.29. 
When patients were evaluated based on age groups, the most 
common age range was 61-70 years with 28.2%, as seen in Figure 
1. This was followed by the range of 71-80 years (24.4%) and 51-
60 years (19.2%). Accordingly, 71.8% of the patients were within 
51-80 years. The distribution of MM-diagnosed patients by year 
between 2005 and 2014 is presented in Figure 2. Of the patients, 
78.2% (n=61) had cutaneous melanoma, 8.9% had solid organ 
melanoma, 2.5% had ocular and mucosal melanoma, and there 
were no records accessible for six (7.6%) patients. The most 
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common tumor localization among the patients was lower 
extremities with 29.4% (n=23). Based on the frequency, other 
localizations were the head and neck with 25.6% (n=20), the trunk 
with 12.8%, and the upper extremities with 10.2%. Furthermore, 
the tumor was identified in ocular, gastric, rectal, hepatic, ovary, 
ileal, and urethral localizations. The most common histopathological 
type was nodular malignant melanoma with 35.8% (n=28) in 
patients with accessible data. Additionally, there was superficial MM 
in six patients, pigmented and acral lentiginous MM in two patients 
each, and amelanotic MM in one patient. Based on TNM 
classification, 26.9% (n=21) of the patients were stage 4, 17.9% 
(n=14) were stage 3, and 14.1% (n=11) were stage 2. Given the 
patient distribution based on the Clark and Breslow staging, 26.9% 
(n=21) of the patients were Clark stage 4, which was the most 
common, and 37.1% (n=29) were Breslow stage 4. There was 
metastasis in 61.5% (n=48) of the patients. The most common 
region for metastasis was the lungs with 28.2% (n=22). 
 
Furthermore, nine patients each (11.5%) had metastasis in the 
liver, bone, and lymph node, seven patients had metastasis in the 
brain, two patients had metastasis in the adrenals, and one patient 
each had metastasis of the ovaries, spinal, tonsillar, and appendix 
metastasis. Again, there was metastasis in multiple foci in 11 
patients. Demographics and pathological data of patients are 
summarized in Table 1. Mean survival time after diagnosis was 14.9 
months. The median overall survival time was 16.9 months in 
females and 12.6 months in males. Stage was found as a prognostic 
factor for survival in melanoma patients. Given these data, it seems 
that patients are generally diagnosed late and therefore treated 
late. Consequently, this results in increased MM mortality and 
morbidity. It was established that 52 (66.6%) of the patients 
included in the study died. Median overall survival in all patients was 
14.9 months (95% CI 10.9 - 18.8 months). Median overall survival 
time was 16.9 months (95% CI 9.8 - 24.1) in females and 12.6 
months (95% CI 7.9 - 17.4) in males (p=0.055). Median survival 
times by stage were 18.1 months at stage 2 (95% CI 5.6 - 30.5), 
19.4 months at stage 3 (95% CI 0.0 - 42.5), and 9.3 months at 
stage 4 (95% CI 6.9 - 11.7). As is seen, there was a significant 
reduction in survival time at stage 4 (p=0.012, Figure 3). By age, 
median time was 12.6 months (95% CI 6.4 - 18.8) under the age of 
50 years and 15.2 months (95% CI 10.3 - 20.2) above the age of 
50 years (p=0.195). By tumor localization, median time was 18.4 
months (95% CI 11.6 - 25.2) for head-neck localization, 9.6 months 
(95% CI 6.3 - 13.0) for the trunk, 23.9 months (95% CI 11.7 - 
36.1) for the upper extremities and 13.6 months (95% CI 10.1 - 
17.1) for the lower extremities. Based on these results, there was a 
reduction in the limit of statistical significance level for trunk 
localization (p=0.056) (Figure 3). In the multivariate Cox analysis, 
only the stage from these parameters statistically significantly 
affected survival [Odds ratio (OR): 0.54; (95% CI 0.16-1.82, 
p=0.02, Table 2. There was no statistically significant difference 
between tumor localization, histopathological type, Clark and 





A malignant melanoma is a tumor with poor prognosis, which 
develops mostly from the skin, but also from other tissues 
containing melanocyte such as mucosa, eye, and meninges. The 
study by Chang et al. reported that 91.2% of the patients had skin-
based melanoma, 5.3% had ocular melanoma, 1.3% had mucosal 
melanoma, and 2.2% had melanoma of unknown primary origin [8]. 
In the present study, the most common was cutaneous MM 
(78.2%). Most of MMs are seen in adults; however, there may be 
cases in children, especially developing from congenital nevi. Three 
hundred fifty-five melanoma patients are under the age of 45 years. 
The mean age at diagnosis is 52 years. The female/male ratio is 
approximately 1:1 in USA and Australia [1, 2, 9]. Studies from 
Turkey reported the mean age to be 45-60 years. With a slightly 
higher male number in male/female ratio, Simsek et al. found a 
higher number of females in their study [10-13]. Studies from Italy, 
Holland, Spain, and Portugal reported that patients were mostly 
within the age range of 40-70 years and MM was more common in 
females [14-17]. In Asia, Chi et al. reported that 82.2% of 522 MM 
patients were aged 65 years and above [3]. Seventy-five percent of 
our patients were aged 50-80 years and the male/female ratio was 
1:1.29. Although the number of males was slightly higher, it was 
not statistically significant. Four histological subtypes of MM were 
defined as superficial spreading MM, nodular MM, lentigo MM, and 
acral lentiginous MM. Superficial malignant melanomas account for 
70% of all melanomas. They are mostly located in the trunk in 
males and the legs in females. Nodular MM is the second most 
common type with 15-30%, mostly at the age of 50-60 years. It is 
the type with the poorest prognosis. It is mostly located in the 
trunk, head, and neck. It is generally diagnosed in the advanced 
stage. Lentigo MM accounts for 5-15% of melanomas and it is 
usually seen at the age of 60-80 years. Acral lentiginous MM is a 
very rare type (2-3%) and seen at the age of 60-70 years [1]. 
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In Australia, MM was reported mostly as the superficial type, located 
in the trunk in males and the lower extremities in females [4,5]. 
Studies from Europe (Italy, Holland, Spain, and Portugal) reported 
that the most common MM type was superficial with the most 
common tumor localization in the trunk and lower extremities [14-
17]. Studies from Asia found acral lentiginous MM as the most 
common type and palmoplantar region as the most common 
localization [3]. The study by Moreno et al. from Brazil and studies 
from Argentina, Uruguay, and Chile found that the most common 
histological type was superficial MM and the most common 
localization was extremities and trunk in females and males [5,18]. 
Studies from Turkey reported nodular MM as the most common MM 
type, whereas Tas et al. reported superficial MM as the most 
common type [10]. The most common localizations were the lower 
extremities and the head-neck region [10-13]. The present study 
found nodular MM as the most common type, consistent with 
studies from Turkey but different from studies from Europe and the 
US. In terms of localization, the most common region was the lower 
extremities and the head-neck region, consistent with the results of 
all studies. Concerning the localisation of the tumour, it was 
observed to involve different regions of the gastrointestinal system 
(GIS) (i.e. stomach, rectum, liver and ileum) following the 
involvement of extremities, head & neck and truncal region. 
Anorectal region is only the third to skin and eye as the most 
frequent locations of melanomas [19]. Primary malignant melanoma 
of the GIS is a rare occurrence. Lesions observed in the GIS usually 
represent the metastases of melanomas on the skin with no 
identifiable primary focus [20]. Melanoma of the stomach is one of 
the common types of melanomas that involve the GIS. The primary 
origin of a melanoma of the stomach is very unlikely and can be 
accepted only in the confirmed absence of any other primary lesions 
[21]. One of our patients had stomach involvement. 
  
One of the histological characteristics of MM is Breslow thickness 
(invasion depth) and it is the strongest determinant for lifetime. 
Additionally, multiple histological characteristics should be specified, 
including Clark´s level of invasion, ulceration, presence of tumor-
infiltrating lymphocytes, mm2/mitoses, regression, vascular 
invasion, perineural invasion, and microscopic satellites. For staging, 
the TNM (tumor-lymph node-metastasis) staging system is used, 
which was established by the AJCC [22]. In studies from the US and 
Europe, MM is usually diagnosed in the early stage. A study from 
the US reported that 62.6% of the patients were diagnosed at TNM 
stage 0 and 1. In studies from Europe, the most common were 
Breslow 1, Clark IV, and TNM stage 1 [14-17]. In Africa, most of the 
MM cases were found at TNM stage 3 or higher [5]. In Brazil, 
Moreno et al. reported Breslow 1, Clark IV, and TNM stage 1 as the 
most common, whereas Clark 3-4 was the most common in 
Australia [18]. In studies from Asia, the most common were Breslow 
1, Clark stage 3, and TNM stage 2 [3]. Studies from Turkey reported 
that most of the patients were at Breslow stage 3-5, Clark stage IV, 
and TNM stage 3-4 [10-13]. In the present study, the findings for 
Breslow 4, Clark IV, and TNM stage 4 were consistent with data 
reported from Turkey. These results suggest that MM is diagnosed 
late in Turkey compared to other countries and developed countries 
in particular. First metastasis in MM is frequently sentinel by 
lymphatic spread, i.e. to the first lymph node along the tumor´s 
lymphatic drainage. In the advanced stage of the disease, the skin, 
soft tissue, lung, liver, brain, bone, and bowel metastases are 
common sites through hematogenous spread. It rarely metastasizes 
to heart and breast [9, 22]. As reported by Tas et al. lung 





Malignant melanoma data are also important for the optimal 
utilization of effective methods and healthcare resources to prevent 
the disease. In order to minimize MM mortality and morbidity, not 
only society but also the physicians from primary and secondary 
care hospitals should become familiar with melanoma, awareness 
should be raised, and the importance of UV exposure should be 
expressed. In this respect, a significant role falls into dermatologists 
and dermatology society in particular. The primary preventive 
strategy should aim for sun protection and avoiding sunburns, 
especially in children and adolescents. Additionally, individuals who 
are light-skinned and in the at-risk group should be periodically 
checked, these data should be recorded, and the patients and their 
families should be warned in this regard. 
 
What is known about this topic 
 The melanoma incidence has shown a significant increase 
for the last few decades around the world; 
 Seventy-five percent of deaths from skin cancers are due 
to melanoma. Due to the poor prognosis and fast course, 
it is also an important public health issue. 
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What this study adds 
 In order to minimize MM mortality and morbidity, not only 
the society but also physicians from primary and 
secondary care hospitals should become familiar with 
melanoma; 
 Individuals who are light-skinned and in the at-risk group 
should be periodically checked, these data should be 
recorded, and the patients and their families should be 
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Table 1: Demographic and pathological characteristics of patients 
  Patient (n) % 
Site 
  
Skin 61 78.2 
Organ 7 8.9 
Mucosal 2 2.5 
Ocular 2 2.5 
Gender 
  
Male 44 56.4 
Female  34 43.6 
Anatomic Location 
  
Lower extremities 23 29.4 
Head-Neck 20 25.6 
Trunk 10 12.8 
Other 25 32 
Histopathological type 
  
Nodular MM 28 35.8 
Superficial MM 6 7.6 
Other 5 6.4 





2 4 5.1 
3 7 8.9 
4 21 26.9 
5 3 3.8 
Unknown 43 55.1 
Breslow 
  
2 1 1.2 
3 4 5.1 
4 29 37.1 
Unknown 44 56.4 
TNM 
  
2 11 14.1 
3 14 17.9 
4 21 26.9 
Unknown 32 41 
Metastasis site 
  
Lung 22 28.2 
Liver  9 11.5 
Lymph node 9 11.5 
Histopathologic findings Positive patients Total 
Perineural invasion 1 18 
Lymphovascular invasion 6 19 
Satellite and intransit metastasis 2 14 
Ulceration 10 21 
 
 
















Table 2: Factors of determining survival (according to the Cox regression model) 
  p OR 
%95 CI 
Lower bound Upper bound 
Age 0.989 1.00 0.964 1.04 
Gender 0.427 1.44 0.584 3.56 
Stage 0.033 2.31 1.7 5.00 
Tumor location 0.678 1.18 0.54 2.58 
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Figure 3: Survival rates according to tumor location and TNM staging 
 
